When we consider the remarks the president made to NBC yesterday suggesting most of our trading partners could see a tariff rate of between 15 and 20% being implemented. Was that the president just riffing or should we expect that the baseline 10% rate currently in place is going to go higher. The baseline way to think about this is to look at the original levels of reciprocal tariffs and the letters that have just gone out where the president has lifted the tariffs from the 10% to a higher rate, roughly tr ...

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial. Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of June 30, 2025: 201 ...

Core Viewpoint - President Trump has threatened to impose tariffs of up to 200% on imported pharmaceuticals, indicating a significant shift in trade policy that could impact the pharmaceutical industry in the U.S. [1][2] Group 1: Tariff Announcement - The proposed tariffs would be set at a very high rate, potentially reaching 200% [1] - Trump mentioned that there would be a grace period of about one to one and a half years for drugmakers to adjust before the tariffs take effect [2] - This announcement marks Trump's most significant comment on pharmaceutical tariffs since the initiation of a Section 232 investigation in April [3] Group 2: Industry Impact - The planned tariffs are expected to negatively affect pharmaceutical companies, which have warned that such levies could increase costs, deter investments in the U.S., and disrupt the drug supply chain, ultimately putting patients at risk [4] - The pharmaceutical industry is already facing challenges from Trump's drug pricing policies, which threaten their profitability and ability to invest in research and development [4] Group 3: Manufacturing Incentives - Trump has stated that the tariffs would encourage drug companies to relocate their manufacturing operations back to the U.S. [5] - Companies like Eli Lilly, Johnson & Johnson, and AbbVie are reportedly increasing their investments in the U.S. as domestic drug manufacturing has significantly declined over the past few decades [5]

Bicycle Therapeutics Investor Presentation • May 2025 Forward-looking statements Bicycle® molecules are short peptides chemically constrained with a central scaffold that can induce diverse structures Scaffold Chemical modification with scaffold Short linear peptide + Bicycle® molecule This presentation may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "antici ...

NASDAQ: LNTH Lantheus Investor Presentation Building on our Foundation to Power the Future of Radiopharmaceuticals May 2025 © 2025 Lantheus. All rights reserved. Safe Harbor Statements Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Ac ...

Under the agreement, Cyclotek will produce and provide doses of Tb-labeled RAD 402 to support Radiopharm's upcoming Phase 1 clinical trial in prostate cancer in Australia. The Phase 1 trial is anticipated to start in the second half of 2025. RAD 402 preclinical data package complete; demonstrates safety and promising biodistribution profile Ethics approval and Phase 1 clinical trial start in prostate cancer anticipated in 2H 2025 SYDNEY and BUNDOORA, Australia, June 24, 2025 (GLOBE NEWSWIRE) -- Radiopharm T ...

NASDAQ: LNTH Lantheus Investor Presentation BUILDING ON OUR FOUNDATION TO POWER THE FUTURE OF RADIOPHARMACEUTICALS 2025 Truist Securities MedTech Conference June 17, 2025 © 2025 Lantheus. All rights reserved. Safe Harbor Statements Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor ...

12 June 2025 | 2:12PM HKT Sino Biopharmaceutical (1177.HK): 46th Annual Global Healthcare Conference — Key Takeaways Presenter: Kyler Lei - Head of Capital Markets Bottom Line: Management re-iterated guidance of double-digit sales growth for 2025, driven by 25% y/y growth of innovative drugs and positive growth from the generic portfolio de-risked from VBP impacts. With multiple innovative assets under active negotiations with MNC pharma and global leading biotech companies, the company highlighted one majo ...

Mr. Hunter brings more than 40 years of experience building and leading commercial organizations in the biopharmaceutical industry, including leadership roles at Validus Pharmaceuticals, Relialab and Novartis Led launch of Tonix Medicines, acquisition of migraine assets Zembrace® SymTouch® and Tosymra®, and recruitment of commercial leadership team Appointment strengthens commercial strategy and governance as Tonix prepares for potential launch of TNX-102 SL for fibromyalgia this year CHATHAM, N.J., June 13 ...

BEDFORD, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced the presentation of new data highlighting two oncology radiodiagnostic agents will be presented at the upcoming 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, taking place June 21-24, 2025, in New Orleans, LA. Prese ...